Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Real Time Quote from BATS)

$4.40 USD

4.40
3,562,437

-0.01 (-0.11%)

Updated Apr 23, 2024 03:57 PM ET

After-Market: $4.38 -0.02 (-0.45%) 4:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

BioCryst Pharmaceuticals, Inc. [BCRX]

Reports for Purchase

Showing records 1 - 20 ( 174 total )

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

02/27/2024

Company Report

Pages: 7

Orladeyo Can Continue Near-Term Growth Strategy - Oral Differentiation; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

01/26/2024

Industry Report

Pages: 6

INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for BCRX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

11/06/2023

Company Report

Pages: 6

Biocryst’s Structure-Based Drug Design Reflective of the Next Chapter of the Complement Mediated Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

11/03/2023

Company Report

Pages: 7

Orladeyo Near-Term Growth Strategy and Upside From Drug Discovery RD Day; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

08/04/2023

Company Report

Pages: 7

Positive Orladeyo Growth Trajectory Continues to Define Near-Term; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

05/04/2023

Company Report

Pages: 7

Orladeyo Growth and Global Scope—Setting Foundation For Broader Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

02/22/2023

Company Report

Pages: 7

Orladeyo Expansion Met With Separate BCX10013 Pipeline Questions; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

12/16/2022

Daily Note

Pages: 4

BCX10013 Reflects Nimble Pivot For Complement Pipeline; Data Expected 1Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

11/02/2022

Company Report

Pages: 7

What’s Next? Considerations for the Complement-Mediated Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

08/05/2022

Company Report

Pages: 7

FDA Lifts BCX9930 Partial Clinical Hold While Orladeyo Delivers in HAE

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

05/06/2022

Company Report

Pages: 7

A Tale of Two Cities-As Orladeyo Expands, BCX9930 Re-Evaluates Dosing Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

02/24/2022

Company Report

Pages: 7

Orladeyo Expansion Within Oral HAE, and BCX9930 Pipeline in a Molecule Potential

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

01/11/2022

Company Report

Pages: 7

Orladeyo Asserts HAE Positioning - Planting Flag for Oral Prophylaxis

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

11/04/2021

Company Report

Pages: 7

Orladeyo Launch Reflects Oral Demand-Global HAE Upside on Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BCRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

08/06/2021

Company Report

Pages: 7

Orladeyo Impetus Supports Demand for Oral HAE Prophylactic; Raising PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

05/07/2021

Company Report

Pages: 7

Orladeyo Off to the Races, Along With Pivotal PNH Trials Expected 2H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

03/24/2021

Company Report

Pages: 8

Spotlight On BXC9930, Early Success for Factor D Inhibition; PT to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

02/26/2021

Company Report

Pages: 7

Orladeyo Three-Pronged Commercial Strategy With BCX9930 in its Wake

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party